Day: February 16, 2022

BRIGHTON, Mich, Feb. 16, 2022 (GLOBE NEWSWIRE) — CGE Energy, Inc.’s (OTC: CGEI) subsidiary, Aradatum, a cleantech telecommunications technology company has assembled a best-in-class engineering and manufacturing team as the company prepares for their initial pilot installations of their next generation wireless tower infrastructure in early 2023. The Company is pleased to announce that it has expanded its strategic development partners by recently appointing Michigan technology and design firm Twisthink to lead Aradatum’s tower control system development. Twisthink is a digital consultancy that specializes in digital strategy and solutions. Custom IoT and control system solutions is one of their core competencies. Powered by Human-Centered Design and agile principles, Twisthink helps their clients discern what deserves to be built,...

Company reports positive clinical data assessing cardiovascular risk for patent-pending microdose compound DENVER, Feb. 16, 2022 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced the inclusion of a novel molecule with potentially heart-safe microdose enabling properties in their family of psilocin analogs. The Company has named this group of patent pending molecules MYCO-005. In December of 2021, Mydecine announced a patent application covering multiple families of psilocin analogs, MYCO-005. This family of second-generation molecules directly addresses delivery and stability concerns with the first-generation compounds. The Company reported that...

SAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) — Salona Global Medical Device Corporation (the “Company” or “Salona”) (TSXV: SGMD), is pleased to announce that it has closed its previously announced bought deal private placement of units of the Company (the “Units”). A total of 7,749,000 Units were sold at a price of $0.55 per Unit for aggregate gross proceeds of approximately $4.26 million (the “Offering”), which included the partial exercise of the Underwriters’ (as defined below) option. The Offering was underwritten by a syndicate of underwriters led by Beacon Securities Limited and included Canaccord Genuity Corp. and Leede Jones Gable Inc. (collectively, the “Underwriters”). Each Unit consists of one common share of the Company (each, a “Common Share”) and one Common Share purchase warrant (each, a “Warrant”), with each Warrant...

Minim, Inc. Minim and Link Net Enter PartnershipLatest partnership marks continuation of Minim’s collaboration to increase access to intelligent Wi-Fi systems MANCHESTER, N.H., Feb. 16, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Minim, Inc., (NASDAQ: MINM), the creator of intelligent Wi-Fi software and Motorola home networking products under an exclusive global brand license, today announces their partnership with PT Link Net Tbk (“Link Net” or the Company; stock code: “LINK”) one of the leading cable TV and fixed broadband internet providers in Indonesia with the brand “First Media”, as part of their ongoing activity as a participant in the TIP OpenWiFi initiative. This new relationship will bring Minim’s TIP OpenWiFi-driven routers and mesh systems and its mobile app deployed to Link Net subscribers throughout the country.   Featuring...

SOUTH SAN FRANCISCO, Calif. and OAKLAND, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) and the American Heart Association (AHA) Bay Area today announced a three-year collaboration to accelerate education and awareness of heart disease. Within the collaboration, Cytokinetics will provide funding and support for several initiatives led by AHA Bay Area. In 2022, Cytokinetics will sponsor the Research Roundtable, a life-sciences industry fundraising event. Cytokinetics will also support several Bay Area Heart Walks by establishing an enhanced VIP area for patients and caregivers, which will provide additional space for friends, families, coworkers and neighbors to demonstrate their commitment to their health and to honor loved ones with heart disease or stroke. Additionally, Cytokinetics will elevate...

Costerfield gold reserves increase by 24%; Björkdal maintains long mine life TORONTO, Feb. 16, 2022 (GLOBE NEWSWIRE) — Mandalay Resources Corporation (“Mandalay” or the “Company”) (TSX: MND, OTCQB: MNDJF) is pleased to announce updated Mineral Resources and Reserves estimates for its Costerfield gold-antimony mine in Victoria, Australia and its Björkdal gold mine in Skellefteå, Sweden as at December 31, 2021. All dollar amounts in this press release are in U.S. dollars unless otherwise noted. Highlights: CosterfieldProven and Probable Mineral Reserves for contained gold increased by 24%, net of depletion for 2021 production; and Extended mine life by two years to 2027, net of depletion for 2021 production.BjörkdalMaintains long mine life until 2030; Improved geological understanding allowing for upgrade...

VANCOUVER, British Columbia, Feb. 16, 2022 (GLOBE NEWSWIRE) — Icanic Brands Company Inc. (“Icanic” or the “Company”) (TSXV: ICAN) is announcing today that it has been issued a Cease Trade Order (“CTO”) by the British Columbia Securities Commission under National Policy 11-207. On November 30, 2021, the Company announced that, for reasons disclosed below, there would be a delay in the filing of its financial statements and accompanying management’s discussion and analysis for the fiscal year ended July 31, 2021 (the “Annual Filings”) beyond the period prescribed under applicable Canadian securities laws (the “Default Announcement”). In addition, the delay in the annual statements has resulted in the interim financial statements and accompanying management discussion and analysis for the three-month period...

No difference in pharmacokinetics between IV Push and IV Infusion No serious adverse events observed No difference in viral load between IV Push and IV Infusion and no anti-drug antibodies detectedMONTREAL, Feb. 16, 2022 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the presentation of positive results from the Phase 3 study evaluating an intravenous (IV) push method of administration of Trogarzo® for the treatment of human immunodeficiency virus type 1 (HIV-1). The results, presented as a poster at the Conference on Retroviruses and Opportunistic Infections (CROI) held virtually February 12–16, 2022, demonstrated that there was no significant difference...

PORTLAND, Ore., Feb. 16, 2022 (GLOBE NEWSWIRE) — Chalice Brands Ltd. (CSE:CHAL) (OTCQB:CHALF) (“Chalice” or the “Company”), a premier consumer-driven cannabis company specializing in retail, production, processing, wholesale, is pleased to provide a letter to its shareholders and corporate update from Jeff Yapp, President and Chief Executive Officer. The complete letter follows and can be accessed at www.investors.chalicebrandsltd.com. “Dear Fellow Shareholders, As we’ve embarked on a new year, John and I wanted to first and foremost thank you for the continued support. We are delighted with the progress we have made for the Company and the strategic objectives accomplished in 2021 to position Chalice for long-term growth. The foundation of the business is carrying strong momentum into 2022 and the team looks forward to accelerating...

In vilobelimab and pembrolizumab combination arm, the three patients enrolled in the first dosing cohort have been treated for 36 days with no safety concerns Steering Committee unanimously voted to continue study as planned and open enrollment for second dosing cohort Enrollment is also ongoing in vilobelimab monotherapy arm, with no safety concerns identifiedJENA, Germany, Feb. 16, 2022 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced the start of the second dosing cohort of the vilobelimab and PD-1 checkpoint inhibitor, pembrolizumab, combination arm of the Phase II clinical trial in cutaneous squamous cell carcinoma (cSCC). The open label, non-comparative, two-stage, Phase II trial (NCT04812535)...